![](/img/cover-not-exists.png)
EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR ALIROCUMAB 300 MG EVERY 4 WEEKS IN INDIVIDUALS WITH TYPE 2 DIABETES ON MAXIMALLY TOLERATED STATIN THERAPY
Müller-Wieland, Dirk, Rader, Daniel, Moriarty, Patrick, Bergeron, Jean, Langslet, Gisle, Ray, Kausik, Manvelian, Garen, Thompson, Desmond, Bujas-Bobanovic, Maja, Roth, EliVolume:
69
Language:
english
Journal:
Journal of the American College of Cardiology
DOI:
10.1016/s0735-1097(17)35097-0
Date:
March, 2017
File:
PDF, 372 KB
english, 2017